Photo from wikipedia
Background: The survival benefit of Implantable cardioverter defibrillator (ICD) in ischemic cardiomyopathy with an ejection fraction (EF) of ≤35% is well established. However, there remains controversy regarding its benefit in… Click to show full abstract
Background: The survival benefit of Implantable cardioverter defibrillator (ICD) in ischemic cardiomyopathy with an ejection fraction (EF) of ≤35% is well established. However, there remains controversy regarding its benefit in non-ischemic cardiomyopathy (NICM). We performed a meta-analysis
Keywords:
ischemic cardiomyopathy;
meta analysis;
non ischemic;
cardiomyopathy;
cardioverter defibrillator;
implantable cardioverter
Journal Title: Journal of the American College of Cardiology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!